Literature DB >> 24173243

Expression of major histocompatibility complex class I-related chain A/B (MICA/B) in pancreatic carcinoma.

Zilvinas Dambrauskas1, Helena Svensson, Meghnad Joshi, Anders Hyltander, Peter Naredi, Britt-Marie Iresjö.   

Abstract

Major histocompatibility complex class I-related chain A and B (MICA/B) are two stress-inducible ligands that bind to the immunoreceptor NKG2D and play an important role in mediating cytotoxicity of NK and T cells. Release of MIC molecules from the cell surface is thought to constitute an immune escape mechanism of tumor cells and thus could be associated with more aggressive course of tumor growth. In this study, we investigated the expression of MICA/B in ductal pancreatic carcinoma and serum in relation to tumor stage, differentiation and survival. MICA/B expression in tumor tissues and sera from patients with pancreatic cancer were analyzed by immunohistochemical staining (IHC), western blotting and ELISA, respectively. MICA/B expression was present in 17 of 22 (77%) of the tumors but not in normal pancreatic ductal epithelial cells. Poorly differentiated tumors showed more pronounced MICA/B expression compared to differentiated tumors, but did not correlate significantly to other tumor characteristics. MICA/B-negative tumors displayed significantly lower incidence of lymph node metastases (p<0.01), and less mortality within 3 years following resection (p<0.02). In conclusion, tissue levels of MICA/B expression were elevated in pancreatic cancer cells without elevated levels in serum, despite well-recognized acute phase reactants in serum. Poorly differentiated tumors showed high MICA/B expression, which was related to extended tumor lymph node metastases and less frequent long-term survival.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24173243     DOI: 10.3892/ijo.2013.2156

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  14 in total

1.  Soluble MICA is elevated in pancreatic cancer: Results from a population based case-control study.

Authors:  Guillaume Onyeaghala; Heather H Nelson; Bharat Thyagarajan; Amy M Linabery; Angela Panoskaltsis-Mortari; Myron Gross; Kristin E Anderson; Anna E Prizment
Journal:  Mol Carcinog       Date:  2017-05-24       Impact factor: 4.784

2.  MHC I-related chain a expression in gastric carcinoma and the efficacy of immunotherapy with cytokine-induced killer cells.

Authors:  Yu Chen; Jing Lin; Zeng-Qing Guo; Wan-Song Lin; Zhi-Feng Zhou; Chuang-Zhong Huang; Qiang Chen; Yun-Bin Ye
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

Review 3.  Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.

Authors:  Haojun Shi; Ji Li; Deliang Fu
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-07       Impact factor: 4.553

Review 4.  Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy.

Authors:  Jesus I Luna; Steven K Grossenbacher; William J Murphy; Robert J Canter
Journal:  Expert Opin Biol Ther       Date:  2016-12-23       Impact factor: 4.388

Review 5.  Models to Study NK Cell Biology and Possible Clinical Application.

Authors:  Anthony E Zamora; Steven K Grossenbacher; Ethan G Aguilar; William J Murphy
Journal:  Curr Protoc Immunol       Date:  2015-08-03

6.  Effect of surgery on pancreatic tumor-dependent lymphocyte asset: modulation of natural killer cell frequency and cytotoxic function.

Authors:  Francesco Iannone; Alessandra Porzia; Giovanna Peruzzi; Patrizia Birarelli; Bernardina Milana; Luca Sacco; Giuseppe Dinatale; Nadia Peparini; Giampaolo Prezioso; Simone Battella; Roberto Caronna; Stefania Morrone; Gabriella Palmieri; Fabrizio Mainiero; Piero Chirletti
Journal:  Pancreas       Date:  2015-04       Impact factor: 3.327

7.  Fractional uptake of circulating tumor cells into liver-lung compartments during curative resection of periampullary cancer.

Authors:  Caroline Vilhav; Cecilia Engström; Peter Naredi; Ann Novotny; Johan Bourghardt-Fagman; Britt-Marie Iresjö; Annika G Asting; Kent Lundholm
Journal:  Oncol Lett       Date:  2018-09-12       Impact factor: 2.967

8.  Association between MICA polymorphisms, s-MICA levels, and pancreatic cancer risk in a population-based case-control study.

Authors:  Guillaume Onyeaghala; John Lane; Nathan Pankratz; Heather H Nelson; Bharat Thyagarajan; Bruce Walcheck; Kristin E Anderson; Anna E Prizment
Journal:  PLoS One       Date:  2019-06-05       Impact factor: 3.240

9.  Abnormal expression levels of sMICA and NKG2D are correlated with poor prognosis in pancreatic cancer.

Authors:  Jiong Chen; Hong Xu; Xing-Xing Zhu
Journal:  Ther Clin Risk Manag       Date:  2015-12-22       Impact factor: 2.423

10.  MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma.

Authors:  Liang Fang; Jiuyu Gong; Ying Wang; Rongrong Liu; Zengshan Li; Zhe Wang; Yun Zhang; Chunmei Zhang; Chaojun Song; Angang Yang; Jenny P-Y Ting; Boquan Jin; Lihua Chen
Journal:  J Exp Clin Cancer Res       Date:  2014-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.